Journal
JOURNAL OF HEPATOLOGY
Volume 60, Issue 6, Pages 1306-1309Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2014.02.003
Keywords
Liver cancer; Fibrosis; Hepatic stellate cell; Microenvironment; Therapeutics; Genomics
Categories
Funding
- Inserm
- Universite de Rennes 1
- Association Francaise pour l'Etude du Foie
- Agence Nationale de la Recherche
- Institut National du Cancer
- Canceropole Ile-de-France
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most common types of primary tumors in the liver. Although major advances have been made in understanding the cellular and molecular mechanisms underlying liver carcinogenesis, HCC and ICC are still deadly cancers worldwide waiting for innovative therapeutic options. Growing evidence from the literature highlight the critical role of the tumor cell microenvironment in the pathogenesis of cancer diseases. Thus, targeting the microenvironment, particularly the crosstalk between tumor cells and stromal cells, has emerged as a promising therapeutic strategy. This strategy would be particularly relevant for liver cancers which frequently develop in a setting of chronic inflammation and microenvironment remodeling associated with hepatic fibrosis and cirrhosis, such processes in which hepatic stellate cells (HSC) greatly contribute. This review brings a genomic point of view on the alterations of the cellular microenvironment in liver cancers, particularly the stromal tissue within tumor nodules, emphasizing the importance of the crosstalk between tumor cells and stromal cells, notably activated HSC, in tumor onset and progression. Furthermore, potential therapeutic modalities of targeting the stroma and HSC are discussed. (C) 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available